This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BeesFree Enters Consulting Agreement With Chief Scientist, Dr. Francesca Del Vecchio

WEST PALM BEACH, Fla., Nov. 8, 2012 /PRNewswire/ --  BeesFree, Inc. (OTC QB: BEES), the worldwide distributor of BeesVita Plus™ and the Beespenser™, announced today that it has entered into a consulting agreement with Dr. Francesca del Vecchio, the Company's Chief Scientist.  Dr. del Vecchio will continue in her current capacity through October 31, 2015. Dr. del Vecchio is the inventor of both BeesVita Plus™, an innovative composite food supplement for honey bees that works to prevent the effects of Colony Collapse Disorder (CCD), and the Beespenser™, an automated external honey bee feeding system.

Dr. del Vecchio possesses more than 18 years of professional research experience in a variety of academic, corporate and private research and development centers.  She has managed projects in the fields of biology, chemistry, botany and biochemistry.  Her specialty is in the development of advanced techniques for the formulation and preparation of biochemical compounds and DNA sequencing, e.g. DNA library construction, ligation in plasmid cloning vectors and analysis of genomic DNA sequencing results.  Dr. del Vecchio has a Ph.D. in biochemistry from Cambridge University, United Kingdom and a University Degree in Biology from the University of 'La Sapienza' in Rome, Italy.

"We are excited to have someone as talented and knowledgeable as Dr. del Vecchio committed to the company for another three years," stated Mr. David Todhunter, CEO and President of BeesFree, Inc.  "Her knowledge of honey bees both from a scientific perspective and as a beekeeper will help keep our products on the cutting edge.  We believe that her experience and key industry relationships will continue to present the company with opportunities for market expansion."

"I am very happy to be part of a company so dedicated to the health and welfare of honey bees worldwide," stated Dr. del Vecchio.  "I'm looking forward to the challenge of keeping our products at the forefront of technology."

About BeesFree, Inc.   BeesFree, Inc. (OTC QB: BEES), a company focused on developing innovative solutions for the global beekeeping community, owns a patent pending nutritional food supplement that helps honey bees avoid the effects of Colony Collapse Disorder (CCD) and a patent pending automated honey bee feeding system.  Visit www.beesfree.biz to learn more about why the bees are disappearing, and how beekeepers can combat the honey bee decline.

Forward-Looking Statements   Statements about the future expectations of BeesFree, Inc. and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as that term is defined in the Private Securities Litigation Reform Act of 1995. BeesFree, Inc. intends that such forward-looking statements shall be subject to the safe harbors created thereby. Since these statements involve certain risks and uncertainties and are subject to change at any time, BeesFree Inc.'s actual results could differ materially from expected results.

Contact    Investor Relations Contact:TPW Capital, Inc. Thomas Walsh, PresidentTelephone: (201) 424-4573Email: Marketing@beesfree.biz

SOURCE BeesFree, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs